The UK’s National Institute for Health and Care Excellence (Nice) has declined to recommend two new Alzheimer’s drugs for routine NHS use in England. While disappointing for some families affected by dementia, this decision reflects a cautious and evidence-based approach that protects patients and public funds.
The drugs in question – lecanemab, made by Eisai, and donanemab made by Eli Lilly – have received significant attention, with headlines hailing them as “breakthrough” treatments and “miracle” drugs. However, Nice has a long history of closely scrutinising new dementia drugs – and, as in previous cases, it has raised important questions about how much benefits these medicines actually provide.
The main claim is that these drugs can delay the progression of Alzheimer’s by about four to six months in people with early-stage disease. That’s not nothing – but it’s also not the dramatic shift some headlines imply.
